Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis - 18/02/21

Kenneth G. Saag, MD ^a, Tobias J. de Villiers, MD ^b, Peter Alexandersen, MD ^c, Heidi Jacobe, MD ^d, Carrie Kovarik, MD ^e, Victoria P. Werth, MD ^f, Albert Leung, MD, PhD ^g, Avani Desai-Merchant, MS ^g, Julie Mattaliano, BSN ^g, Deborah Gurner, MD, PhD ^{g, ⁎}

^a University of Alabama at Birmingham, Birmingham, Alabama 

^b Mediclinic Panorama and Department of Obstetrics and Gynaecology, University of Stellenbosch, Cape Town, South Africa 

^c Center for Clinical and Basic Research, Vejle, Denmark 

^d Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas 

^e Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 

^f Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania 

^g Merck & Co, Inc, Kenilworth, New Jersey 

^∗Reprint requests: Deborah Gurner, MD, PhD, Mailstop UG3C-54, 351 North Sumneytown Pike, PO Box 1000, North Wales, PA 19454-2505Mailstop UG3C-54, 351 North Sumneytown Pike, PO Box 1000North WalesPA19454-2505